Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of TP53 mutations in a real-world setting
ABSTRACTObjectives: This study aimed to evaluate the incidence and prognostic significance of common cytogenetic and molecular abnormalities in patients with TP53-mutated and non-TP53-mutated acute myeloid leukemia (AML).Methods: We retrospectively analyzed the clinical data of 326 patients with new...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2023.2223866 |
| _version_ | 1797804361127034880 |
|---|---|
| author | Hong Liu Yuye Shi Shandong Tao Yunjie Li Chunling Wang Liang Yu |
| author_facet | Hong Liu Yuye Shi Shandong Tao Yunjie Li Chunling Wang Liang Yu |
| author_sort | Hong Liu |
| collection | DOAJ |
| description | ABSTRACTObjectives: This study aimed to evaluate the incidence and prognostic significance of common cytogenetic and molecular abnormalities in patients with TP53-mutated and non-TP53-mutated acute myeloid leukemia (AML).Methods: We retrospectively analyzed the clinical data of 326 patients with newly diagnosed AML hospitalized in our institution between October 2015 and June 2021. Classification variables were reported as percentages and compared by χ2 tests. Survival rates were evaluated by the Kaplan-Meier method.Results: The incidence of TP53 mutations in AML patients in this clinic was 9.8%, of whom 87.5% patients were over 50 years old. The common concurrent mutations of TP53 were DNMT3A, IDH2, NRAS and TET2. Patients with a TP53 variant allele frequency (VAF) ≤ 40% had better overall survival (OS) than patients with a VAF >40%. Compared with non-TP53-mutated patients, significantly more TP53-mutated patients were gene-fusion negative, +mar, – 7/del (7q), – 5/del (5q), – 17/17p-, – 12/12p-, incomplete (inc) karyotype, or complex karyotype (CK), and had FLT3-ITD or IDH2 mutations, as well as a lower complete remission (CR) rate (31.3%) and higher recurrence rate (80.0%). The 2-year OS rates of TP53-mutated and non-TP53-mutated patients were 18.8% and 47.3%, respectively (P < 0.001). Univariate analysis showed that non-TP53-mutated patients with MLL family gene fusion, +mar or – 17/17p – karyotype, and FLT3-ITD mutations had a poor prognosis, while t(8; 21) karyotype was associated with a better prognosis. TP53-mutated patients with – 7/del (7q) or – 5/del (5q) karyotype had a poor prognosis.Conclusions: The cytogenetic and molecular landscapes differed between TP53-mutated and non-TP53-mutated patients, and some abnormalities had different values between them. |
| first_indexed | 2024-03-13T05:34:58Z |
| format | Article |
| id | doaj.art-df7cc8bab96940b1897b2901ba0eaff3 |
| institution | Directory Open Access Journal |
| issn | 1607-8454 |
| language | English |
| last_indexed | 2024-03-13T05:34:58Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj.art-df7cc8bab96940b1897b2901ba0eaff32023-06-14T10:27:16ZengTaylor & Francis GroupHematology1607-84542023-12-0128110.1080/16078454.2023.2223866Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of TP53 mutations in a real-world settingHong Liu0Yuye Shi1Shandong Tao2Yunjie Li3Chunling Wang4Liang Yu5Department of Hemopathology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Key Laboratory of Nanjing Medical University, Huaian, People’s Republic of ChinaDepartment of Hemopathology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Key Laboratory of Nanjing Medical University, Huaian, People’s Republic of ChinaDepartment of Hemopathology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Key Laboratory of Nanjing Medical University, Huaian, People’s Republic of ChinaDepartment of Hemopathology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Key Laboratory of Nanjing Medical University, Huaian, People’s Republic of ChinaDepartment of Hemopathology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Key Laboratory of Nanjing Medical University, Huaian, People’s Republic of ChinaDepartment of Hemopathology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Key Laboratory of Nanjing Medical University, Huaian, People’s Republic of ChinaABSTRACTObjectives: This study aimed to evaluate the incidence and prognostic significance of common cytogenetic and molecular abnormalities in patients with TP53-mutated and non-TP53-mutated acute myeloid leukemia (AML).Methods: We retrospectively analyzed the clinical data of 326 patients with newly diagnosed AML hospitalized in our institution between October 2015 and June 2021. Classification variables were reported as percentages and compared by χ2 tests. Survival rates were evaluated by the Kaplan-Meier method.Results: The incidence of TP53 mutations in AML patients in this clinic was 9.8%, of whom 87.5% patients were over 50 years old. The common concurrent mutations of TP53 were DNMT3A, IDH2, NRAS and TET2. Patients with a TP53 variant allele frequency (VAF) ≤ 40% had better overall survival (OS) than patients with a VAF >40%. Compared with non-TP53-mutated patients, significantly more TP53-mutated patients were gene-fusion negative, +mar, – 7/del (7q), – 5/del (5q), – 17/17p-, – 12/12p-, incomplete (inc) karyotype, or complex karyotype (CK), and had FLT3-ITD or IDH2 mutations, as well as a lower complete remission (CR) rate (31.3%) and higher recurrence rate (80.0%). The 2-year OS rates of TP53-mutated and non-TP53-mutated patients were 18.8% and 47.3%, respectively (P < 0.001). Univariate analysis showed that non-TP53-mutated patients with MLL family gene fusion, +mar or – 17/17p – karyotype, and FLT3-ITD mutations had a poor prognosis, while t(8; 21) karyotype was associated with a better prognosis. TP53-mutated patients with – 7/del (7q) or – 5/del (5q) karyotype had a poor prognosis.Conclusions: The cytogenetic and molecular landscapes differed between TP53-mutated and non-TP53-mutated patients, and some abnormalities had different values between them.https://www.tandfonline.com/doi/10.1080/16078454.2023.2223866Acute myeloid leukemiamolecular abnormalitynext-generation gene sequencingcytogenetic abnormalityprognosis |
| spellingShingle | Hong Liu Yuye Shi Shandong Tao Yunjie Li Chunling Wang Liang Yu Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of TP53 mutations in a real-world setting Hematology Acute myeloid leukemia molecular abnormality next-generation gene sequencing cytogenetic abnormality prognosis |
| title | Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of TP53 mutations in a real-world setting |
| title_full | Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of TP53 mutations in a real-world setting |
| title_fullStr | Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of TP53 mutations in a real-world setting |
| title_full_unstemmed | Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of TP53 mutations in a real-world setting |
| title_short | Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of TP53 mutations in a real-world setting |
| title_sort | clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of tp53 mutations in a real world setting |
| topic | Acute myeloid leukemia molecular abnormality next-generation gene sequencing cytogenetic abnormality prognosis |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2023.2223866 |
| work_keys_str_mv | AT hongliu clinicalandmolecularcharacteristicsofacutemyeloidleukemiaandthedismalprognosisoftp53mutationsinarealworldsetting AT yuyeshi clinicalandmolecularcharacteristicsofacutemyeloidleukemiaandthedismalprognosisoftp53mutationsinarealworldsetting AT shandongtao clinicalandmolecularcharacteristicsofacutemyeloidleukemiaandthedismalprognosisoftp53mutationsinarealworldsetting AT yunjieli clinicalandmolecularcharacteristicsofacutemyeloidleukemiaandthedismalprognosisoftp53mutationsinarealworldsetting AT chunlingwang clinicalandmolecularcharacteristicsofacutemyeloidleukemiaandthedismalprognosisoftp53mutationsinarealworldsetting AT liangyu clinicalandmolecularcharacteristicsofacutemyeloidleukemiaandthedismalprognosisoftp53mutationsinarealworldsetting |